|
SLC39A10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6304735339645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
3.159000E-04 |
| Normal-vs-Stage3 |
6.74019999813424E-08 |
| Normal-vs-Stage4 |
3.60479999994556E-06 |
| Stage1-vs-Stage2 |
1.001960E-01 |
| Stage1-vs-Stage3 |
3.842500E-04 |
| Stage1-vs-Stage4 |
5.080300E-02 |
| Stage2-vs-Stage3 |
7.559000E-01 |
| Stage2-vs-Stage4 |
8.857000E-01 |
| Stage3-vs-Stage4 |
5.606400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.18713935851156E-14 |
| Normal-vs-AfricanAmerican |
1.57184999999282E-05 |
| Normal-vs-Asian |
3.44959999998284E-06 |
| Caucasian-vs-AfricanAmerican |
2.888200E-01 |
| Caucasian-vs-Asian |
8.358400E-01 |
| AfricanAmerican-vs-Asian |
4.452200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.08209951688832E-10 |
| Normal-vs-Female |
1.63802305053196E-12 |
| Male-vs-Female |
8.730400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(41-60Yrs) |
4.69809746661554E-11 |
| Normal-vs-Age(61-80Yrs) |
3.84669999997644E-06 |
| Normal-vs-Age(81-100Yrs) |
1.007780E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.818800E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.165490E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.820400E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.072830E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.390400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.958400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.933710E-02 |
| Classical-VS-Follicular |
1.709380E-01 |
| Classical-VS-Other |
1.441980E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
4.666200E-01 |
| Tall-VS-Other |
9.181400E-01 |
| Tall-VS-Normal |
4.13960000000824E-06 |
| Follicular-VS-Other |
5.424400E-01 |
| Follicular-VS-Normal |
2.81790000000726E-07 |
| Other-VS-Normal |
7.558700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.08150205142033E-11 |
| Normal-vs-N1 |
1.03529999995189E-06 |
| N0-vs-N1 |
1.051420E-01 |
|
|
